Nanoparticles: a Promising Modality in the Treatment of Sarcomas

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2010 May 28

PMID 20505985

Citations 6

Authors

Michiro Susa

Lara Milane

Mansoor M Amiji

Francis J Hornicek

Zhenfeng Duan

Affiliations

Soon will be listed here.

Abstract

Improvements in surgical technique, chemotherapy, and radiotherapy have enhanced the prognosis of sarcoma patients, but have since reached a plateau in recent years. Novel approaches have been sought but with limited results. Nanomedicine offers solutions in diverse areas of sarcoma therapy including diagnosis and treatment. Several varieties of nanoparticles, including multifunctional nanoparticles, are available that localize the biodistribution of conventional chemotherapeutics to the tumor site. Also, nanoparticles loaded with chemotherapeutic drugs have the ability to overcome drug resistance which is a major obstacle impeding the progress of the treatment. Multifunctional nanoparticles, which have the potential to further augment the bioavailability of drugs, are being actively investigated. In this review, we will discuss the application of nanoparticles for improving the treatment of sarcoma patients.

Citing Articles

Translation of nanotechnology-based implants for orthopedic applications: current barriers and future perspective.

Chen L, Zhou C, Jiang C, Huang X, Liu Z, Zhang H Front Bioeng Biotechnol. 2023; 11:1206806.

PMID: 37675405 PMC: 10478008. DOI: 10.3389/fbioe.2023.1206806.

Comparison of Clinical Effects of Temozolomide Single Agent and Combined Doxorubicin in the Treatment of Glioma.

Liu Y, Chen L J Healthc Eng. 2022; 2022:7995385.

PMID: 35345663 PMC: 8957447. DOI: 10.1155/2022/7995385.

Nanotechnology in orthopedics: a clinically oriented review.

Smith W, Hudson P, Ponce B, Rajaram Manoharan S BMC Musculoskelet Disord. 2018; 19(1):67.

PMID: 29499666 PMC: 5833027. DOI: 10.1186/s12891-018-1990-1.

p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines.

Ye S, Shen J, Choy E, Yang C, Mankin H, Hornicek F Cancer Chemother Pharmacol. 2015; 77(2):349-56.

PMID: 26698867 PMC: 4749432. DOI: 10.1007/s00280-015-2944-z.

Assessing the barriers to image-guided drug delivery.

Lanza G, Moonen C, Baker Jr J, Chang E, Cheng Z, Grodzinski P Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013; 6(1):1-14.

PMID: 24339356 PMC: 3967549. DOI: 10.1002/wnan.1247.

References

Patil Y, Swaminathan S, Sadhukha T, Ma L, Panyam J . The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials. 2009; 31(2):358-65. PMC: 2783414. DOI: 10.1016/j.biomaterials.2009.09.048. View

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Helman L, Meltzer P . Mechanisms of sarcoma development. Nat Rev Cancer. 2003; 3(9):685-94. DOI: 10.1038/nrc1168. View

Bozzi F, Tamborini E, Negri T, Pastore E, Ferrari A, Luksch R . Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors. Cancer. 2007; 109(8):1638-45. DOI: 10.1002/cncr.22587. View

Abolhoda A, Wilson A, Ross H, Danenberg P, Burt M, Scotto K . Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res. 1999; 5(11):3352-6. View

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G . Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2007; 8(1):59-73. DOI: 10.1038/nri2216. View

Sebolt-Leopold J, Herrera R . Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004; 4(12):937-47. DOI: 10.1038/nrc1503. View

Fang J, Deng D, Nakamura H, Akuta T, Qin H, Iyer A . Oxystress inducing antitumor therapeutics via tumor-targeted delivery of PEG-conjugated D-amino acid oxidase. Int J Cancer. 2007; 122(5):1135-44. DOI: 10.1002/ijc.22982. View

Gambhir S . Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002; 2(9):683-93. DOI: 10.1038/nrc882. View

10.

Elbashir S, Lendeckel W, Tuschl T . RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001; 15(2):188-200. PMC: 312613. DOI: 10.1101/gad.862301. View

11.

Wu H, Hait W, Yang J . Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003; 63(7):1515-9. View

12.

Sundaram S, Trivedi R, Durairaj C, Ramesh R, Ambati B, Kompella U . Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res. 2009; 15(23):7299-308. PMC: 2787834. DOI: 10.1158/1078-0432.CCR-09-1745. View

13.

Miller R, Young Jr J, Novakovic B . Childhood cancer. Cancer. 1995; 75(1 Suppl):395-405. DOI: 10.1002/1097-0142(19950101)75:1+<395::aid-cncr2820751321>3.0.co;2-w. View

14.

Seymour L, Ferry D, Anderson D, Hesslewood S, Julyan P, Poyner R . Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol. 2002; 20(6):1668-76. DOI: 10.1200/JCO.2002.20.6.1668. View

15.

Northfelt D, Martin F, Working P, Volberding P, Russell J, Newman M . Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol. 1996; 36(1):55-63. DOI: 10.1002/j.1552-4604.1996.tb04152.x. View

16.

Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J . Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther. 2009; 8(8):2122-30. PMC: 2766237. DOI: 10.1158/1535-7163.MCT-09-0115. View

17.

Fujimoto T, Ichikawa H, Akisue T, Fujita I, Kishimoto K, Hara H . Accumulation of MRI contrast agents in malignant fibrous histiocytoma for gadolinium neutron capture therapy. Appl Radiat Isot. 2009; 67(7-8 Suppl):S355-8. DOI: 10.1016/j.apradiso.2009.03.063. View

18.

Zhang Y, So M, Rao J . Protease-modulated cellular uptake of quantum dots. Nano Lett. 2006; 6(9):1988-92. PMC: 2553895. DOI: 10.1021/nl0611586. View

19.

Minko T, Kopeckova P, Kopecek J . Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int J Cancer. 2000; 86(1):108-17. DOI: 10.1002/(sici)1097-0215(20000401)86:1<108::aid-ijc17>3.0.co;2-8. View

20.

Scotlandi K, Manara M, Nicoletti G, Lollini P, Lukas S, Benini S . Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 2005; 65(9):3868-76. DOI: 10.1158/0008-5472.CAN-04-3192. View